Company Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer.
It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer.
The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma.
It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells.
Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
| Country | United States |
| IPO Date | Jul 20, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 331 |
| CEO | Dr. Sushil Patel Ph.D. |
Contact Details
Address: 500 Unicorn Park Drive Woburn, Massachusetts United States | |
| Website | https://www.replimune.com |
Stock Details
| Ticker Symbol | REPL |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001737953 |
| CUSIP Number | 76029N106 |
| ISIN Number | US76029N1063 |
| Employer ID | 82-2082553 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sushil Patel Ph.D. | Chief Executive Officer & Director |
| Emily Luisa Hill | Chief Financial Officer |
| Andrew Schwendenman | Chief Accounting Officer & Treasurer |
| Christopher Sarchi | Chief Commercial Officer |
| Dr. Konstantinos Xynos M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Dr. Robert Coffin Ph.D. | Founder, Chief Scientist & Director |
| Paul Bullock | Chief Manufacturing Officer & Framingham Site Head |
| Philip Astley-Sparke F.S.A. | Executive Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 04, 2024 | 8-K/A | [Amend] Current Report |
| Nov 27, 2024 | 8-K | Current Report |
| Nov 26, 2024 | 424B5 | Filing |
| Nov 26, 2024 | 8-K | Current Report |
| Nov 25, 2024 | 424B5 | Filing |
| Nov 21, 2024 | 8-K | Current Report |
| Nov 20, 2024 | 4 | Filing |
| Nov 20, 2024 | 4 | Filing |
| Nov 19, 2024 | S-8 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |